MX370791B - Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida. - Google Patents

Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida.

Info

Publication number
MX370791B
MX370791B MX2017002913A MX2017002913A MX370791B MX 370791 B MX370791 B MX 370791B MX 2017002913 A MX2017002913 A MX 2017002913A MX 2017002913 A MX2017002913 A MX 2017002913A MX 370791 B MX370791 B MX 370791B
Authority
MX
Mexico
Prior art keywords
dimethoxyquinazolin
dimethylbenzofuran
carboxamide
crystalline forms
oxy
Prior art date
Application number
MX2017002913A
Other languages
English (en)
Other versions
MX2017002913A (es
Inventor
Wu Zhenping
Li Wenji
Chu Yuping
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55458346&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370791(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2017002913A publication Critical patent/MX2017002913A/es
Publication of MX370791B publication Critical patent/MX370791B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al campo farmacéutico, proporciona nuevas formas cristalinas, solvatos y sus formas cristalinas, del compuesto 6-((6,7-dimetoxiquinazolin-4-il)oxi)-N, 2-dimetilbenzofuran-3-carboxamida, composiciones farmacéuticas, así como también los métodos de preparación de las mismas y su uso.
MX2017002913A 2014-09-10 2015-09-07 Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida. MX370791B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410456350.9A CN105461702A (zh) 2014-09-10 2014-09-10 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
PCT/CN2015/089035 WO2016037550A1 (en) 2014-09-10 2015-09-07 Crystalline forms of 6- ( (6, 7-dimethoxyquinazolin-4-yl) oxy) -n,2-dimethylbenzofuran-3-carboxamide

Publications (2)

Publication Number Publication Date
MX2017002913A MX2017002913A (es) 2017-06-06
MX370791B true MX370791B (es) 2020-01-08

Family

ID=55458346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002913A MX370791B (es) 2014-09-10 2015-09-07 Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida.

Country Status (31)

Country Link
US (3) US10519142B2 (es)
EP (1) EP3191475B1 (es)
JP (2) JP6655608B2 (es)
KR (2) KR102221722B1 (es)
CN (3) CN105461702A (es)
AU (1) AU2015316010B2 (es)
BR (1) BR112017004000B1 (es)
CA (1) CA2958666C (es)
CL (1) CL2017000540A1 (es)
CY (1) CY1123892T1 (es)
DK (1) DK3191475T3 (es)
EA (1) EA034730B1 (es)
ES (1) ES2819242T3 (es)
HK (1) HK1231479A1 (es)
HR (1) HRP20201501T1 (es)
HU (1) HUE050580T2 (es)
IL (1) IL250647B (es)
LT (1) LT3191475T (es)
MX (1) MX370791B (es)
MY (1) MY176618A (es)
PE (1) PE20170661A1 (es)
PH (1) PH12017500451A1 (es)
PL (1) PL3191475T3 (es)
PT (1) PT3191475T (es)
RS (1) RS60829B1 (es)
SG (1) SG11201701544UA (es)
SI (1) SI3191475T1 (es)
TW (1) TWI718105B (es)
UA (1) UA120371C2 (es)
WO (1) WO2016037550A1 (es)
ZA (1) ZA201701320B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN111164085B (zh) 2017-09-29 2023-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
US11236077B2 (en) 2018-03-30 2022-02-01 Hangzhou Solipharma Co., Ltd. Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
WO2020196871A1 (ja) 2019-03-28 2020-10-01 住友重機械工業株式会社 ショベル
CN113200966B (zh) * 2021-04-06 2022-07-22 深圳大学 一种呋喹替尼衍生物、药物组合物和用途
GB202211142D0 (en) * 2022-07-29 2022-09-14 Macfarlan Smith Ltd Polymorphs, co-crystals and solvates of fruquintinib, processes for the preparation and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101575333B (zh) * 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
CN105461702A (zh) * 2014-09-10 2016-04-06 和记黄埔医药（上海）有限公司 6-(6,7-二甲氧基喹唑啉-4-基氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型

Also Published As

Publication number Publication date
HRP20201501T1 (hr) 2020-12-25
PT3191475T (pt) 2020-09-04
JP2019065019A (ja) 2019-04-25
CN111018846A (zh) 2020-04-17
DK3191475T3 (da) 2020-09-28
ZA201701320B (en) 2020-07-29
US20210276983A1 (en) 2021-09-09
CN105461702A (zh) 2016-04-06
US10519142B2 (en) 2019-12-31
EA201790275A1 (ru) 2017-10-31
CY1123892T1 (el) 2022-03-24
MX2017002913A (es) 2017-06-06
CN111018846B (zh) 2023-06-06
AU2015316010A8 (en) 2017-05-11
WO2016037550A1 (en) 2016-03-17
LT3191475T (lt) 2020-10-12
IL250647A0 (en) 2017-04-30
AU2015316010B2 (en) 2018-06-14
US20170283399A1 (en) 2017-10-05
SI3191475T1 (sl) 2021-02-26
PH12017500451A1 (en) 2017-07-31
TW201609715A (zh) 2016-03-16
RS60829B1 (sr) 2020-10-30
IL250647B (en) 2020-11-30
CN106604919A (zh) 2017-04-26
JP6655608B2 (ja) 2020-02-26
AU2015316010A1 (en) 2017-04-27
EP3191475B1 (en) 2020-07-29
EP3191475A1 (en) 2017-07-19
BR112017004000A2 (pt) 2017-12-05
CN106604919B (zh) 2019-11-15
MY176618A (en) 2020-08-18
KR102221722B1 (ko) 2021-03-03
HK1231479A1 (zh) 2017-12-22
SG11201701544UA (en) 2017-03-30
JP2017526710A (ja) 2017-09-14
UA120371C2 (uk) 2019-11-25
US11958838B2 (en) 2024-04-16
NZ729884A (en) 2020-09-25
ES2819242T3 (es) 2021-04-15
BR112017004000B1 (pt) 2023-10-24
EP3191475A4 (en) 2018-10-03
KR20170042662A (ko) 2017-04-19
PE20170661A1 (es) 2017-05-18
CA2958666A1 (en) 2016-03-17
CA2958666C (en) 2020-10-06
HUE050580T2 (hu) 2020-12-28
TWI718105B (zh) 2021-02-11
US11046674B2 (en) 2021-06-29
EA034730B1 (ru) 2020-03-13
KR20190018056A (ko) 2019-02-20
PL3191475T3 (pl) 2021-01-11
CL2017000540A1 (es) 2017-09-15
US20200140420A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12017500732A1 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12015502146A1 (en) 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2015013048A (es) Forma cristalina de un compuesto ansiolitico.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
FG Grant or registration